Ji Hyun Kim, Baek Gyu Jun, Minjong Lee, Hye Ah Lee, Tae Suk Kim, Jeong Won Heo, Da Hye Moon, Seong Hee Kang, Ki Tae Suk, Moon Young Kim, Young Don Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim, Dae Hee Choi
Clin Mol Hepatol 2022;28(3):540-552. Published online May 6, 2022
Background/Aims Sepsis-3 criteria and quick Sequential Organ Failure Assessment (qSOFA) have been advocated to be used in defining sepsis in the general population. We aimed to compare the Sepsis-3 criteria and Chronic Liver Failure-SOFA (CLIF-SOFA) scores as predictors of in-hospital mortality in cirrhotic patients admitted to the emergency department (ED) for infections.
Methods A total of 1,622 cirrhosis patients admitted at the ED for infections were assessed retrospectively. We analyzed their demographic, laboratory, and microbiological data upon diagnosis of the infection. The primary endpoint was inhospital mortality rate. The predictive performances of baseline CLIF-SOFA, Sepsis-3, and qSOFA scores for in-hospital mortality were evaluated.
Results The CLIF-SOFA score proved to be significantly better in predicting in-hospital mortality (area under the receiver operating characteristic curve [AUROC], 0.80; 95% confidence interval [CI], 0.78–0.82) than the Sepsis-3 (AUROC, 0.75; 95% CI, 0.72–0.77, P<0.001) and qSOFA (AUROC, 0.67; 95% CI, 0.64–0.70; P<0.001) score. The CLIF-SOFA, CLIF-C-AD scores, Sepsis-3 criteria, septic shock, and qSOFA positivity were significantly associated with in-hospital mortality (adjusted hazard ratio [aHR], 1.24; 95% CI, 1.19–1.28; aHR, 1.13; 95% CI, 1.09–1.17; aHR, 1.19; 95% CI, 1.15–1.24; aHR, 1.88; 95% CI, 1.42–2.48; aHR, 2.06; 95% CI, 1.55–2.72; respectively; all P<0.001). For CLIF-SOFA scores ≥6, in-hospital mortality was >10%; this is the cutoff point for the definition of sepsis.
Conclusions Among cirrhosis patients presenting with infections at the ED, CLIF-SOFA scores showed a better predictive performance for mortality than both Sepsis-3 criteria and qSOFA scores, and can be a useful tool of risk stratification in cirrhotic patients requiring timely intervention for infection.
Citations
Citations to this article as recorded by
Interpretable model for early prediction of 28-day mortality in patients with cirrhosis and sepsis: a multi-cohort ICU study Xin Xu, Jingjing Li, Haijing Yu, Jiaquan Huang BMC Gastroenterology.2026;[Epub] CrossRef
A Serum DLL1 and CRP dual-marker model for bacterial infection detection in patients with decompensated cirrhosis: A dual-cohort diagnostic study Juanjun Huang, Luhu Yu, Debin Zeng, Yulin Wang, Zhi Wang, Jian Chen, Wei Zhu Science Progress.2025;[Epub] CrossRef
Correlation between systemic inflammatory response syndrome and prognosis of patients with cirrhosis and hepatic encephalopathy Kaiyue Zhang, Ziqun Qu, Rongyu Tang, Hongliang Dong, Jing Fan, Wei Ye BMC Gastroenterology.2025;[Epub] CrossRef
Management of patients with cirrhosis in the emergency department: Implications for hospitalization outcomes Sandeep Sikerwar, Sohrab Zand, Peter Steel, Arun Jesudian Liver Transplantation.2024; 30(1): 94. CrossRef
Current Status of Prognostic Evaluation Model and Treatment of Acute-on-Chronic Liver Failure 念 刘 Advances in Clinical Medicine.2024; 14(04): 2500. CrossRef
Prevalence and predictors of multidrug-resistant bacteremia in liver cirrhosis Aryoung Kim, Byeong Geun Song, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Yong-Han Paik, Moon Seok Choi, Joon Hyeok Lee, Myung Ji Goh The Korean Journal of Internal Medicine.2024; 39(3): 448. CrossRef
Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment Do Seon Song, Hee Yeon Kim, Young Kul Jung, Tae Hyung Kim, Hyung Joon Yim, Eileen L Yoon, Ki Tae Suk, Jeong-ju Yoo, Sang Gyune Kim, Moon Young Kim, Young Chang, Soung Won Jeong, Jae Young Jang, Sung-Eun Kim, Jung-Hee Kim, Jung Gil Park, Won Kim, Jin Mo Ya Clinical and Molecular Hepatology.2024; 30(3): 388. CrossRef
Correspondence to editorial on “Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment” Do Seon Song, Dong Joon Kim Clinical and Molecular Hepatology.2024; 30(4): 1012. CrossRef
Cirrhosis Management in the Intensive Care Unit Thomas N. Smith, Alice Gallo de Moraes, Douglas A. Simonetto Seminars in Liver Disease.2023; 43(01): 117. CrossRef
Tae Suk Kim, Ji Hoon Kim, Baek hui Kim, Young-Sun Lee, Yang Jae Yoo, Seong Hee Kang, Sang-June Suh, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun
Clin Mol Hepatol 2017;23(4):340-346. Published online June 20, 2017
Since sorafenib was introduced in 2007 for treating advanced hepatocellular carcinoma (HCC), 15 patients have achieved a complete response (CR) in advanced HCC. However, only four of these reports can be regarded as real CRs involving adequate assessments including imaging, serum tumor markers, and histologic examinations of completely resected specimens. A 54-year-old man with hepatitis C virus (HCV)-related liver cirrhosis (LC) presented to our unit. A CT scan demonstrated a 3.8-cm arterial hypervascular/portal-washout mass in the right lobe and invasion in the right portal vein. Twelve weeks after beginning sorafenib therapy, the AFP level was normalized and a CT scan showed a prominent decrease in the hepatic mass and a significant decrease in the volume of portal vein thrombosis (PVT). The patient received a right liver hemihepatectomy after 12 months. No viable tumor cells were found in the resected specimen, and there was no thrombotic obstruction of the portal vein. Twelve months later the patient showed no clinical evidence of HCC recurrence. This is the first case of CR in HCC treatment following sorafenib with histologically confirmed HCVrelated HCC without LC evidence, HCC with PVT, and a follow-up of longer than 12 months. This case seems to be an extremely unusual clinical outcome in advanced HCC.
Citations
Citations to this article as recorded by
The novel predictive nomograms for early death in metastatic hepatocellular carcinoma: A large cohort study Yue Wang, Long Ge, Yan Cai Medicine.2024; 103(1): e36812. CrossRef
Liver resection and transplantation in the era of checkpoint inhibitors Parissa Tabrizian, Rebecca Marino, Pierce K.H. Chow JHEP Reports.2024; 6(11): 101181. CrossRef
Sorafenib as first-line treatment for patients with primary hepatocellular carcinoma: an outcome evaluation Dung Thi Nguyen, Duong Hoang Nguyen, Van Thi Hong Nguyen Journal of International Medical Research.2023;[Epub] CrossRef
Automatic prediction of hepatic arterial infusion chemotherapy response in advanced hepatocellular carcinoma with deep learning radiomic nomogram Ziming Xu, Chao An, Feng Shi, He Ren, Yuze Li, Song Chen, Jiaqi Dou, Yajie Wang, Shaozhen Yan, Jie Lu, Huijun Chen European Radiology.2023; 33(12): 9038. CrossRef
Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors Junichi Arita, Akihiko Ichida, Rihito Nagata, Yuichiro Mihara, Yoshikuni Kawaguchi, Takeaki Ishizawa, Nobuhisa Akamatsu, Junichi Kaneko, Kiyoshi Hasegawa Journal of Hepato-Biliary-Pancreatic Sciences.2022; 29(7): 732. CrossRef
Durable objective response to sorafenib and role of sequential treatment in unresectable hepatocellular carcinoma Kuo-Wei Huang, Pei-Chang Lee, Yee Chao, Chien-Wei Su, I-Cheng Lee, Keng-Hsin Lan, Chi-Jen Chu, Yi-Ping Hung, San-Chi Chen, Ming-Chih Hou, Yi-Hsiang Huang Therapeutic Advances in Medical Oncology.2022;[Epub] CrossRef
A Practical Nomogram and Risk Stratification System Predicting the Cancer-Specific Survival for Patients With Advanced Hepatocellular Carcinoma Dashuai Yang, Yang Su, Fangrui Zhao, Chen Chen, Kailiang Zhao, Xiangyun Xiong, Youming Ding Frontiers in Oncology.2022;[Epub] CrossRef
Lenvatinib is independently associated with the reduced risk of progressive disease when compared with sorafenib in patients with advanced hepatocellular carcinoma Soojin Kim, Kyung Hyun Kim, Beom Kyung Kim, Jun Yong Park, Sang Hoon Ahn, Do Young Kim, Seung Up Kim Journal of Gastroenterology and Hepatology.2021; 36(5): 1317. CrossRef
Outcomes of reduction hepatectomy combined with postoperative multidisciplinary therapy for advanced hepatocellular carcinoma Yoh Asahi, Toshiya Kamiyama, Tatsuhiko Kakisaka, Tatsuya Orimo, Shingo Shimada, Akihisa Nagatsu, Takeshi Aiyama, Yuzuru Sakamoto, Hirofumi Kamachi, Akinobu Taketomi World Journal of Gastrointestinal Surgery.2021; 13(10): 1245. CrossRef
Complete Pathological Response of Hepatocellular Carcinoma with Portal Vein Thrombosis Treated with Sorafenib—Report of a Case— Tetsushi MIZUTANI, Mizuo HASHIMOTO, Hiroaki USUI, Tomoki KOBAYASHI, Motonobu NISHIMURA, Kenji SAKAGUCHI Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association).2021; 82(3): 635. CrossRef
Modeling Hepatocellular Carcinoma Cells Dynamics by Serological and Imaging Biomarkers to Explain the Different Responses to Sorafenib and Regorafenib Piero Colombatto, Coskun Ozer Demirtas, Gabriele Ricco, Luigi Civitano, Piero Boraschi, Paola Scalise, Daniela Cavallone, Filippo Oliveri, Veronica Romagnoli, Patrizia Bleve, Barbara Coco, Antonio Salvati, Lucio Urbani, Ferruccio Bonino, Maurizia Rossana Cancers.2021; 13(9): 2064. CrossRef
Laparoscopic bypass surgery as palliative treatment for duodenal obstruction due to lymph node metastasis invasion of hepatocellular carcinoma Akane Kurosugi, Tetsuhiro Chiba, Terunao Iwanaga, Hidemi Unozawa, Takafumi Sakuma, Naoto Fujita, Kengo Kanayama, Hiroaki Kanzaki, Keisuke Koroki, Kazufumi Kobayashi, Soichiro Kiyono, Ryo Nakagawa, Naoya Kanogawa, Masato Nakamura, Takayuki Kondo, Tomoko Sa Kanzo.2021; 62(10): 656. CrossRef
Sorafenib Treatment has the Potential to Downstage Advanced Hepatocellular Carcinoma before Liver Resection Alessandra Bertacco, Alessandro Vitale, Claudia Mescoli, Umberto Cillo Personalized Medicine.2020; 17(2): 83. CrossRef
A case report: Long-term complete response of metastatic hepatocellular carcinoma obtained after discontinuation of 2-month sorafenib monotherapy Suguru Hirose, Kazunori Ishige, Masamichi Yamaura, Tsuneo Mizui, Yoshiki Komatsu, Masaomi Nagase, Masashi Sato, Junji Hattori, Masato Endo, Naoyuki Hasegawa, Kuniaki Fukuda, Ichinosuke Hyodo Clinical Journal of Gastroenterology.2020; 13(5): 902. CrossRef
MTL-CEBPA, a Small Activating RNA Therapeutic Upregulating C/EBP-α, in Patients with Advanced Liver Cancer: A First-in-Human, Multicenter, Open-Label, Phase I Trial Debashis Sarker, Ruth Plummer, Tim Meyer, Mikael H. Sodergren, Bristi Basu, Cheng Ean Chee, Kai-Wen Huang, Daniel H. Palmer, Yuk Ting Ma, T.R. Jeff Evans, Duncan R.C. Spalding, Madhava Pai, Rohini Sharma, David J. Pinato, James Spicer, Sarah Hunter, Vinee Clinical Cancer Research.2020; 26(15): 3936. CrossRef
Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma Mi Na Kim, Seung Min Lee, Jin Sung Kim, Seong Gyu Hwang Cancer Chemotherapy and Pharmacology.2019; 84(4): 809. CrossRef
Reversion of tumor hepatocytes to normal hepatocytes during liver tumor regression in an oncogene-expressing transgenic zebrafish model Yan Li, Ira Agrawal, Zhiyuan Gong Disease Models & Mechanisms.2019;[Epub] CrossRef
Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases Giovanni Brandi, Michela Venturi, Stefania De Lorenzo, Francesca Garuti, Giorgio Frega, Andrea Palloni, Ingrid Garajovà, Francesca Abbati, Gioconda Saccoccio, Rita Golfieri, Maria Abbondanza Pantaleo, Maria Aurelia Barbera Cancer Communications.2018; 38(1): 1. CrossRef
Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure? Matthias Pinter, Wolfgang Sieghart memo - Magazine of European Medical Oncology.2018; 11(3): 185. CrossRef
First
Prev
